The African Swine Fever Isolate ASFV-Kenya-IX-1033 Is Highly Virulent and Stable after Propagation in the Wild Boar Cell Line WSL.
African swine fever virus
Kenyan isolate
genotype IX
virulence
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
29 08 2022
29 08 2022
Historique:
received:
18
07
2022
revised:
19
08
2022
accepted:
23
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
We describe the characterization of an African swine fever genotype IX virus (ASFV-Kenya-IX-1033), which was isolated from a domestic pig in western Kenya during a reported outbreak. This includes the efficiency of virus replication and in vivo virulence, together with genome stability and virulence, following passage in blood macrophages and in a wild boar lung cell line (WSL). The ASFV-Kenya-IX-1033 stock retained its ability to replicate in primary macrophages and retained virulence in vivo, following more than 20 passages in a WSL. At the whole genome level, a few single-nucleotide differences were observed between the macrophage and WSL-propagated viruses. Thus, we propose that the WSL is suitable for the production of live-attenuated ASFV vaccine candidates based on the modification of this wild-type isolate. The genome sequences for ASFV-Kenya-IX-1033 propagated in macrophages and in WSL cells were submitted to GenBank, and a challenge model based on the isolate was developed. This will aid the development of vaccines against the genotype IX ASFV circulating in eastern and central Africa.
Identifiants
pubmed: 36146718
pii: v14091912
doi: 10.3390/v14091912
pmc: PMC9505471
pii:
doi:
Substances chimiques
Nucleotides
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Virol. 2021 Jun 24;95(14):e0012321
pubmed: 33952643
Viruses. 2021 Nov 15;13(11):
pubmed: 34835091
J Virol. 2015 Jun;89(11):6048-56
pubmed: 25810553
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Arch Virol. 2014 Sep;159(9):2421-8
pubmed: 24793370
Vaccine. 2016 Sep 7;34(39):4698-4705
pubmed: 27521231
Vaccine. 2018 Jan 29;36(5):707-715
pubmed: 29254837
Sci Rep. 2018 Oct 2;8(1):14714
pubmed: 30279544
Virus Genes. 2015 Apr;50(2):303-9
pubmed: 25645905
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Front Genet. 2021 Aug 30;12:733674
pubmed: 34527025
Virus Genes. 2018 Feb;54(1):111-123
pubmed: 29143187
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
J Virol. 2006 Nov;80(21):10514-21
pubmed: 17041222
Sci Rep. 2018 Jan 23;8(1):1449
pubmed: 29362418
J Virol. 2017 Nov 30;91(24):
pubmed: 28978700
J Gen Virol. 2017 Jul;98(7):1806-1814
pubmed: 28721858
J Virol. 2020 Mar 17;94(7):
pubmed: 31969432
PLoS One. 2015 Nov 30;10(11):e0142889
pubmed: 26618713
Arch Virol. 2003 Apr;148(4):693-706
pubmed: 12664294
Antiviral Res. 2019 May;165:34-41
pubmed: 30836106
Transbound Emerg Dis. 2021 Mar;68(2):813-823
pubmed: 32696552
Nucleic Acids Res. 2011 May;39(9):e57
pubmed: 21306991
J Virol. 2017 Oct 13;91(21):
pubmed: 28814514
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
Transbound Emerg Dis. 2021 Nov;68(6):3018-3019
pubmed: 34609795
J Virol. 2020 Apr 16;94(9):
pubmed: 32075923
Viruses. 2020 Jul 28;12(8):
pubmed: 32731642
Viruses. 2021 Feb 15;13(2):
pubmed: 33672090
Sci Rep. 2018 Feb 16;8(1):3154
pubmed: 29453406
Emerg Microbes Infect. 2020 Dec;9(1):1245-1253
pubmed: 32515659
Sci Rep. 2017 Sep 4;7(1):10369
pubmed: 28871180
J Virol. 2015 Feb;89(4):2324-32
pubmed: 25505073
Vaccine. 2011 Jun 20;29(28):4593-600
pubmed: 21549789
Viruses. 2021 Nov 01;13(11):
pubmed: 34835004
Sci Rep. 2021 Jun 22;11(1):13081
pubmed: 34158551
Front Vet Sci. 2020 Aug 04;7:495
pubmed: 32851049